DonCorleone77 Posted - 3 days ago

$PRTA Prothena announces review on birtamimab mechanism Prothena Corporation announced the publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential best-in-class anti-amyloid treatment for AL amyloidosis. The publication can be found in the latest issue of Leukemia & Lymphoma, an international peer-reviewed journal that publishes research on all aspects of hematological malignancies. AL amyloidosis is an idiopathic, rare, progressive and often fatal disease characterized by amyloid deposits that build up in vital organs leading to damage, dysfunction and failure. The risk of early mortality is especially high in patients with significant cardiac involvement as there are no current treatment options that target existing amyloid deposits in these patients. Birtamimab binds to a highly conserved cryptic epitope which is only exposed in misfolded kappa and lambda light chain protein. Birtamimab binds and neutralizes soluble, toxic LC aggregates and binds and clears insoluble AL amyloid deposits, without affecting normally folded LC proteins. This mechanism of action is complementary to the current standard of care therapy for AL amyloidosis which does not target the existing toxic LC aggregates and amyloid deposits. "Birtamimab was designed to clear deposited amyloid from vital organs and is the only treatment that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis, which was demonstrated in a post hoc analysis of the Phase 3 VITAL placebo-controlled clinical trial," said Hideki Garren, M.D., Ph.D., Chief Medical Officer, Prothena. "Birtamimab is being evaluated in patients with Mayo Stage IV AL amyloidosis, who are at high risk of early mortality, in the ongoing confirmatory Phase 3 AFFIRM-AL clinical trial."

Stock_Titan Posted - 3 days ago

$PRTA Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma https://www.stocktitan.net/news/PRTA/prothena-announces-review-on-birtamimab-mechanism-of-action-and-yoooy0hs97cy.html

diamondtoes Posted - 2 weeks ago

$PRTA This looks worth watching, we're getting hit with rising end-of-life cost soundbytes in media lately. 👀

GoddessWen Posted - 03/23/24

$PRTA undervalued, underestimated, under the radar...bought shares

ElijahJobs Posted - 03/22/24

$ANVS LOL Not the first time I see aggressive SAVA fanboy posts like this. But the truth may be both $ANVS and $SAVA are dogs with fleas in my humble opinion. Go with $PRTA instead. JMO

sepsis74 Posted - 03/20/24

$PRTA wasn't Prothena exploring a sale of itself only back in 4Q 2023? What ever happened to that? The stock was close to $50 at that time.

ElijahJobs Posted - 1 month ago

$PRTA Probably the most undervalued biotech stock in comparison to the potentials of the currently active pipeline. JMO

ElijahJobs Posted - 1 month ago

$PRTA Close to forming a double bottom at this level near 25. Oh, I am so excited with anticipation of Alzheimer's data... Very Bullish.

ElijahJobs Posted - 1 month ago

$PRTA Started to accumulate June calls. I am betting that, by then, the P1 Alzheimer's data will be out. JMO

AfroChicken Posted - 1 month ago

$PRTA $QQQ $DIA $SPY

nicknyc85 Posted - 1 month ago

$PRTA $QQQ $DIA $SPY bottom is in..🤑

Stock_Titan Posted - 1 month ago

$PRTA Prothena to Participate in Upcoming Healthcare Conferences https://www.stocktitan.net/news/PRTA/prothena-to-participate-in-upcoming-healthcare-czo3tkat8r4q.html

Rounderssss4 Posted - 02/27/24

$PRTA Would be a great time to release some positive p1 results

Oversold_Gems Posted - 02/26/24

$PRTA

ElijahJobs Posted - 02/24/24

$PRTA I think that this stock is at the bottom or very near it now. A huge potential within this year. I took an initial position on Friday. A good chance that its two Alzheimer's P2 data readouts would change the world. JMO

FatLoads Posted - 02/23/24

$PRTA thinking about buying in. What’s all the recent downtrend aboot?

Rounderssss4 Posted - 02/23/24

$PRTA Wonder if they got news coming up . Time for the pump

GoddessWen Posted - 02/23/24

$PRTA Offering This registration statement contains: • a base prospectus, which covers the offering, issuance and sale by us of the securities identified therein from time to time in one or more offerings; and • an equity distribution agreement prospectus, which covers the offering, issuance and sale by us of up to a maximum aggregate offering price of $250,000,000 of the registrant’s ordinary shares that may be issued and sold from time to time under an equity distribution agreement, as amended, with Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co., RBC Capital Markets, LLC, and Citizens JMP Securities, LLC https://d18rn0p25nwr6d.cloudfront.net/CIK-0001559053/077ff722-5153-414f-8f65-b0b7128a09bf.html

DonCorleone77 Posted - 02/22/24

$PRTA Prothena files to sell ordinary shares, no amount given

Coooos Posted - 02/22/24

$PRTA any thoughts on the new appointment to the board that has undertaken numerous BOs by big pharma? Any read-through here?

AnaChart Posted - 02/20/24

$PRTA https://anachart.com/wp-content/uploads/ana_temp/1708441327_soc-img.jpg

Thestocktraderhubzee Posted - 02/20/24

WATCHLIST FEB 20 2024.. $COIN JMP Securities Maintains Market Outperform on Coinbase Glb, Raises Price Target to $220 $BPMC JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target $MLM Stephens & Co. Maintains Overweight on Martin Marietta Materials, Raises Price Target to $605 $XOMA HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target $PRTA RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $35

ElijahJobs Posted - 2 months ago

$PRTA Did they talk about any potential date for releasing the two P2 Alzheimer's data? Thanks.

GoddessWen Posted - 2 months ago

high potential stocks for 2024 imo: $ANVS $PRTA $ALT $ACAD and of course.. $IOVA now with this very important approval

swingingtech Posted - 2 months ago

$PRTA $BMY $NVO $RHHBY https://wallstreetwaves.com/prothena-prta-q4-earnings-miss-estimates-on-higher-rd-expense/

nycmax2002 Posted - 2 months ago

$PRTA we jamming. Company said trial didn't fail and all the partners happy. Back to fixing this option chain... 400% iv today

OpenOutcrier Posted - 2 months ago

$PRTA (-10.0% pre) Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights - BW https://ooc.bz/l/25312

Rounderssss4 Posted - 2 months ago

$PRTA down another 8% premarket for what ?

GoddessWen Posted - 2 months ago

$PRTA Prothena Corp plc's 2023 financials reveal a significant net loss, contrasting sharply with the prior year's profit. This shift is linked to increased R&D spending, notably in neurodegenerative and rare peripheral amyloid disease trials. Elevated general and administrative costs hint at operational expansion, potentially for commercialization prep. Their partnership with Bristol Myers Squibb, evident in a $55 million payment, signals future development support. However, projected 2024 cash burn and year-end balance stress the need for clinical success for financial sustainability.

GoddessWen Posted - 2 months ago

$PRTA “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company. The next 12 to 18 months have the potential to transform Prothena with multiple upcoming clinical readouts across our robust portfolio,” said Gene Kinney, Ph.D., President and Chief Executive Ocer, Prothena. " https://s201.q4cdn.com/351053094/files/doc_news/Prothena-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Financial-Guidance-and-Business-Highlights-2024.pdf